Menu

Dozens of Editorial Board Members Resign from Journal

More than 70 editors left the Journal of Molecular Medicine after SpringerNature closed an editorial office and selected a new editor-in-chief.

Feb 6, 2018
Kerry Grens

ISTOCK, SEAN_KUMAMost of the editorial board of the Journal of Molecular Medicine quit in protest after the publisher, SpringerNature, appointed a different editor-in-chief than editors had recommended and closed an office in Germany.

Retraction Watch reports that on December 1, more than 70 editorial board members, including three former editors-in-chief, wrote in a letter that “the unilateral decision of SpringerNature to disregard the recommendations of the editorial board without engaging in any dialogue or discussion with the editorial board has jeopardized the future and scholarly legacy of the Journal.”

The editors had wanted to install Martin Lohse of the Max Delbrück Center for Molecular Medicine as the editor-in-chief to succeed Detlev Ganten of the Charité Foundation. SpringerNature instead selected Ari Waisman, an immunology researcher at the University Medical Center of the Johannes Gutenberg-University, Mainz. “As a logical step to this new direction for the journal, Springer decided to reorganise the editorial office in close collaboration with the newly appointed editor-in-chief to provide him with the best support we can,” the publisher tells Retraction Watch.

“The decision by Springer to select a new editor at a new location, communicated in a few email lines a few weeks before the actual transfer and never discussed with anybody, made the large majority of the editorial board resign,” Lohse tells Retraction Watch.

As of today, two dozen editorial board members are listed on the journal’s website. Five signatories of the letter remain on the board’s list, although Springer says it is contacting each former board member to confirm their decisions and updating its website.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.